Chronic Kindey Disease (CKD) Models and Efficacy Services

Anti-Tumor Drug Efficacy Evaluation
Humanized Immune Checkpoint Mouse Models and Efficacy Services
Autoimmune Disease Efficacy Evaluation
Autoimmune Nephropathy Models and Efficacy ServicesAsthma Models and Efficacy ServicesSystemic Lupus Erythematosus (SLE) Models and Efficacy ServicesSjögren's Syndrome Models and Efficacy ServicesNeuroimmune Diseases Models and Efficacy ServicesAutoimmune Dermatoses Models and Efficacy ServicesInflammatory Bowel Disease (IBD) Models and Efficacy ServicesRheumatoid Arthritis (RA) Models and Efficacy ServicesImmune Reconstitution Autoimmune Disease Models and Efficacy Services
Metabolic Disease Efficacy Evaluation
Obesity Models and Efficacy ServicesType II Diabetes Models and Efficacy ServiceType I Diabetes Models and Efficacy ServicesAndrogenetic Alopecia (AGA) Models and Efficacy ServicesMASH Models and Efficacy ServicesChronic Liver Fibrosis Models and Efficacy ServicesAcute Liver Injury Models and Efficacy ServicesCholestasis Models and Efficacy ServicesAlcohol-related Liver Disease (ALD) Models and Efficacy ServicesChronic Kindey Disease (CKD) Models and Efficacy ServicesActue Kindey Disease (AKD) Models and Efficacy ServicesDiabetes Nephropathy (Diabetic Kidney Disease) Models and Efficacy ServicesSarcopenia Models and Efficacy ServicesGout/Hyperuricemia Models and Efficacy ServicesFemale Reproduction Models and Efficacy Services
Neurological Disease Efficacy Evaluation
Behavioral AnalysisIn Vivo Drug Efficacy EvaluationDelivering Therapeutics Across the Blood-Brain Barrier (BBB)Parkinson’s Disease Rat Model
Cardiovascular Diseases Efficacy Evaluation
Heart Failure Models and Efficacy ServicesHypertension Models and Efficacy ServicesAtherosclerosis Models and Efficacy ServicesAdvanced Cardiovascular and Metabolic Complication Models and Efficacy ServicesHyperlipidemia Models and Efficacy ServicesHypertropic Cardiomyopathy Models and Efficacy ServicesStroke Models and Efficacy ServicesThrombosis Models and Efficacy Services
Infectious Disease Efficacy Evaluation
About Our Biosafety LaboratoryIn vitro Drug Efficacy EvaluationIn vivo Drug Dfficacy Evaluation
Respiratory Disease Efficacy Evaluation
Acute Lung Injury (ALI) ModelsIdiopathic Pulmonary Fibrosis (IPF) ModelsChronic Obstructive Pulmonary Disease (COPD) ModelsBronchiectasis ModelsPulmonary Function Test
Disease Rat Models
60% HFD Induced DIO Rat ModelsHFHSD+STZ Induced Type II Diabetes Model in SD Rat45％HFHS+STZ Induced Type I Diabetes Models in SD RatCDAHFD-induced Rat MASH ModelCCL4-induced Chronic Liver Fibrosis Models in SD Rat5/6 Nephrectomy-induced Rat CKD ModelAdenine-induced Rat CKD ModelOVX-induced Rat Osteoporosis Model2K1C-induced Hypertension Model in SD RatMCAO-induced CIS Model in SD Rat
Bioanalytical Services
Phenotyping Services
Oncology PlatformMetabolism PlatformEfficacy and Pathology Platform
Non-GLP Toxicity Assessment Services
Cell Therapy & Gene Therapy Efficacy Evaluation

Chronic kidney disease (CKD) is a long - term condition characterized by the gradual loss of kidney function over time. The kidneys, responsible for filtering waste, excess fluids, and regulating electrolytes in the body, become damaged, often due to factors like diabetes, high blood pressure, glomerulonephritis, or genetic disorders. As CKD progresses, symptoms may include fatigue, swelling, changes in urination patterns, and high blood pressure. In advanced stages, it can lead to kidney failure, requiring treatments such as dialysis or a kidney transplant. Early detection through regular screenings and management of risk factors are crucial to slow disease progression and improve patients' quality of life.


5/6 Nephrectomy-induced chronic kidney disease model


The 5/6 nephrectomy-induced chronic kidney disease model is an experimental model widely used to study chronic kidney disease (CKD). By surgically removing a large portion of the kidney, this model mimics the reduction in renal function and compensatory changes. The remaining nephrons undergo compensatory hyperfiltration, leading to increased intraglomerular pressure and subsequent glomerulosclerosis. Additionally, the impaired glomerular filtration barrier and the gradual loss of nephron function ultimately result in renal failure. This model is valuable for studying the pathophysiology of CKD and testing potential therapeutic interventions.


Study outline


图片1.png


1. Nephrectomy induced kidney injury


1.1 Significantly decreased body weight after 5/6 nephrectomy


2.jpeg

Data presented as Mean ± SD, n=15-32, *,**,*** represented G1-sham vs. G2-5/6 nephrectomy, P<0.05, P<0.01, P<0.001.


1.2 Increased UACR after 5/6 nephrectomy


3.jpeg

Data presented as Mean ± SD, n=15-32, *,**** represented G1-sham vs.G2-5/6 nephrectomy , P<0.05, P<0.0001.


1.3 Increased serum CREA after 5/6 nephrectomy


4.jpeg

Data presented as Mean ± SD, n=15-32, **** represented G1-sham vs.G2-5/6 nephrectomy ,  P<0.0001.


1.4 B6 mice show no glomerulosclerosis and slight tubulointerstitial fibrosis in kidney after surgery


5.jpeg


1.5 Survival rate: the postoperative survival rate is approximately 96%


6.png

TALK WITH OUR EXPERTS

GemPharmatech is committed to protecting and respecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please click below to say how you would like us to contact you:

In order to provide you with the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please click the checkbox below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.